Revvity (NYSE:RVTY) Hits New 12-Month Low - Should You Sell?

Revvity, Inc. (NYSE:RVTY - Get Free Report) reached a new 52-week low on Tuesday . The stock traded as low as $87.89 and last traded at $89.03, with a volume of 9859 shares trading hands. The stock had previously closed at $89.32.

Analysts Set New Price Targets

RVTY has been the topic of a number of recent research reports. JPMorgan Chase & Co. decreased their target price on Revvity from $120.00 to $100.00 and set a "neutral" rating on the stock in a research report on Tuesday, April 29th. Wall Street Zen lowered Revvity from a "buy" rating to a "hold" rating in a report on Saturday, May 24th. Wells Fargo & Company cut their target price on Revvity from $130.00 to $102.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. Raymond James reaffirmed an "outperform" rating and issued a $120.00 target price (down from $145.00) on shares of Revvity in a research report on Tuesday, April 29th. Finally, Barclays lowered their price target on shares of Revvity from $140.00 to $110.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Five analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $125.64.

Revvity Stock Down 2.1%

The firm has a market cap of $10.66 billion, a price-to-earnings ratio of 40.92, a PEG ratio of 3.82 and a beta of 1.02. The business's 50-day moving average is $94.06 and its 200-day moving average is $107.74. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60.

Revvity (NYSE:RVTY - Get Free Report) last posted its quarterly earnings data on Monday, April 28th. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.05. The company had revenue of $664.76 million during the quarter, compared to analyst estimates of $662.30 million. Revvity had a net margin of 9.81% and a return on equity of 7.68%. The company's revenue was up 2.3% on a year-over-year basis. During the same quarter last year, the business posted $0.98 earnings per share. On average, equities analysts predict that Revvity, Inc. will post 4.94 EPS for the current year.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 8th. Shareholders of record on Friday, July 18th will be given a $0.07 dividend. The ex-dividend date is Friday, July 18th. This represents a $0.28 annualized dividend and a yield of 0.31%. Revvity's payout ratio is 11.91%.

Institutional Trading of Revvity

Several large investors have recently made changes to their positions in RVTY. Assetmark Inc. lifted its position in Revvity by 3,700.0% during the 4th quarter. Assetmark Inc. now owns 266 shares of the company's stock worth $30,000 after buying an additional 259 shares in the last quarter. Optiver Holding B.V. bought a new position in shares of Revvity in the fourth quarter worth about $33,000. Quarry LP lifted its position in shares of Revvity by 45.7% during the fourth quarter. Quarry LP now owns 303 shares of the company's stock worth $34,000 after purchasing an additional 95 shares in the last quarter. Millstone Evans Group LLC acquired a new position in shares of Revvity during the fourth quarter worth approximately $38,000. Finally, Vermillion Wealth Management Inc. bought a new stake in shares of Revvity during the fourth quarter valued at approximately $41,000. Institutional investors own 86.65% of the company's stock.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.